An Improved Benefit-Risk Profile of Duvelisib in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Received 2 or More Prior Therapies
Hematological Oncology - United Kingdom
doi 10.1002/hon.29_2630
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley